Escitalopram-Associated Bradycardia

Mechanism and Risk Context

The European Heart Journal classifies escitalopram as having a propensity for QT prolongation, with maximum dose restrictions imposed by the FDA and EMA, particularly for patients over 60 years 1, 2, 3
SSRIs, as a class, increase the risk of cardiac arrest (OR 1.21) in a Danish nationwide registry study 2, 3
Important medications that can interact with escitalopram to prolong QT include domperidone, ondansetron, palosetron, granisetron, prochlorperazine, olanzapine, venlafaxine, sertraline, and mirtazapine, according to the American College of Cardiology 4

When bradycardia occurs on escitalopram, immediate assessment should include obtaining a 12-lead ECG to evaluate for conduction abnormalities and measure the QTc interval, as recommended by the American College of Cardiology 5
Check for contributing factors, including concomitant medications causing bradycardia, such as beta-blockers, nondihydropyridine calcium channel blockers, digoxin, and amiodarone, as well as electrolyte abnormalities like hypokalemia and hypomagnesemia, according to the American College of Cardiology 4, 6
For acute symptomatic bradycardia with hemodynamic compromise, administer atropine 0.5 mg IV every 3-5 minutes up to 3 mg total, as recommended by the American Heart Association 7, 5

Never combine escitalopram with other QT-prolonging medications without careful monitoring, as this creates additive cardiac risk, according to the American College of Cardiology 8
Do not use escitalopram in patients with congenital long QT syndrome, pre-existing bradycardia, or significant electrolyte abnormalities, as recommended by the American College of Cardiology 8

Among SSRIs, citalopram and escitalopram carry the highest cardiac risk, while paroxetine has the lowest risk of QTc prolongation and should be preferred in high-risk cardiac patients, according to the European Heart Journal 8
Sertraline and fluoxetine represent intermediate-risk alternatives, and the European Heart Journal recommends avoiding citalopram/escitalopram in patients with moderate to high cardiac risk, as stated by the European Society of Cardiology 8

Avoid adding escitalopram + mirtazapine to patients already receiving agents that slow atrioventricular or sinus node conduction (e.g., β‑blockers, calcium‑channel blockers, digoxin) without cardiology consultation – the risk of severe bradycardia and QT‑interval prolongation is heightened in this setting. 9

First‑line pharmacologic therapy is intravenous atropine 0.5–1 mg, repeatable every 3–5 minutes up to a total of 3 mg for hemodynamically unstable bradycardia. 10
If atropine is ineffective, initiate a catecholamine infusion such as epinephrine (2–10 µg/min) or dopamine (2–10 µg/kg/min) to support heart rate and blood pressure. 10
Discontinue both escitalopram and mirtazapine immediately when symptomatic bradycardia with hemodynamic compromise occurs.
If pharmacologic measures fail, consider transcutaneous pacing as a bridge to more definitive therapy. 10